Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (Aß) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237323PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0027865PLOS

Publication Analysis

Top Keywords

alzheimer's disease
12
drug discovery
8
novel neurotrophic
4
neurotrophic drug
4
drug cognitive
4
cognitive enhancement
4
enhancement alzheimer's
4
disease currently
4
currently major
4
major drug
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!